Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mochida Terminates License Agreement for TRPV1 Antagonists with Wyeth
April 26, 2010
- CMIC Licenses L-FABP Diagnostic Technology to Genzyme
April 26, 2010
- AnGes to Discuss Licensing of ILTS with MEDRx
April 26, 2010
- BI Successfully Completes Tender Offer on SSP
April 26, 2010
- GSK Opens Rare Diseases Medicine Development Center in Japan
April 26, 2010
- Kenko.com Appeals Aiming at Online Sale of Classes 1, 2 OTC Drugs
April 26, 2010
- Shionogi's Demand Rejected in Flomox Patent Litigation
April 26, 2010
- Kenporen Members to Report Record-High Deficit of ¥660 Bil.
April 26, 2010
- BI Launches Global Venture Fund
April 26, 2010
- Isentress Recommended for Lack of Effects on Lipids: Dr Hanabusa
April 26, 2010
- MCI Provides Tablet PCs to All MRs from Benesis
April 19, 2010
- Gefitinib Effective for EGFR-Positive NSCLC in First-Line Therapy
April 19, 2010
- GSK to Disclose Payments to Physicians Made in 2009 and Onward
April 19, 2010
- 637 Monitors Certified in 2nd JCROA Monitor Certification Test
April 19, 2010
- Takeda Initiates Overseas PIII Trial of SGN-35 for Lymphoma
April 19, 2010
- Norvasc, Lipitor Most Often Co-prescribed But in Only 4.3% of Patients
April 19, 2010
- Taiyo Can No Longer Be Family-Owned Company: President Aratani
April 19, 2010
- AnGes MG to Codevelop NF-κB Decoy with Shionogi
April 19, 2010
- Ajinomoto Pharm. to Enter Southeast Asian Market
April 19, 2010
- DB on Medicinal Plants Posted on NIBIO Website
April 19, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…